International Congress (XXIII) Endovascular Interventions
London, UK, 4 March 2010 – Lombard Medical Technologies PLC (AIM: LMT), a medical device company focused on device solutions for $1 billion dollar abdominal aortic aneurysm repair market, announces that Dr Peter Phillips, the Company’s Chief Technology Officer and co-inventor of the Aorfix™ implant, has presented data on the use of Aorfix™ at the International Congress (XXIII) Endovascular Interventions in Phoenix, Arizona (1-4th March).
The data presented was from Lombard’s Retrospective Aorfix™ Data Retrieval (“RADAR”) voluntary registry for all Aorfix™ customers. Dr Phillips stated that the Aorfix™ device has been utilized in the largest series of patients with difficult and tortuous anatomy ever studied, yet still had outstanding clinical results, highlighted by a very low incidence of stent migration (0%), wire fracture (<0.25%) and graft limb occlusion (<0.25%) at 12 months in the data set of 461 eligible patients.
In the session attended by many of the leading vascular interventionalists in the country, Dr Phillips also gave a brief update on recruitment into Lombard’s pivotal FDA study for Aorfix™ in which he stated that, to date, more than 175 patients had been recruited into the trial, and that the Company requires 160 patients with follow-up to 12 months for submission to the FDA (minimum 40 low angle and 120 high angle). The Company has now recruited patients in excess of the minima and is on track to have the required number of patients with appropriate follow-up completed during the first half of 2011.
- Ends -
For further information:
Lombard Medical Technologies PLC
Simon Neathercoat, Non-executive Chairman
John Rush, Chief Executive Officer
Tim Hall, Finance Director
Tel: +44 (0) 1235 750800
Evolution Securities Limited
Barry Saint
Tim Redfern
Esther Lee
Tel: +44 (0) 20 7071 4300
Financial Dynamics
Jonathan Birt
Susan Quigley
Tel: +44 (0) 20 7831 3113
Notes to editors
About Lombard Medical
Lombard Medical Technologies PLC is a medical devices group developing stent grafts and other medical products for use in the treatment of vascular disease. The Company’s lead product, Aorfix™, is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAAs), a balloon-like enlargement of the aorta which, if untreated, may rupture and cause death. Approximately 4.5 million people are living with AAA in the developed world and each year 600,000 new cases are diagnosed. The market for endovascular stent grafts for the treatment of AAA is currently worth approximately $900 million and is expected to grow to around $1.6 billion by 2015. Aorfix™ is currently being commercialised in the EU, with a pivotal clinical trial ongoing in the USA.
The Company is headquartered in Oxfordshire, with operations in Ayrshire and Boston, USA.
Further background on the Company can be found at www.lombardmedical.com.